12,372 trials
Kidney Transplantation · Chronic Kidney Failure
Primary: Percent of Participants Surviving With a Functioning Graft by Month 12 — 92.8; 96.5; 95.4 percentage of participants
COPD · OSA
Primary: Control of Nocturnal Hypoventilation — 6.5; 6.7 kPa
Gout
Primary: Proportion of Subjects With an sUA Level That is < 6.0 mg/dL — 0.542; 0.592; 0.279 Proportion of Subjects — p=<0.0001
Prostate Cancer
Primary: Overall Survival (OS) Time — 29.73; 28.65 months — p=0.3667
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline — 5; 49…
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With a Mean Reduction in Plasma Intact Parathyroid Hormone (iPTH) of >/= 30% From Baseline Values at End of…
Chronic Kidney Disease · Hyperparathyroidism, Secondary · Vitamin D Deficiency
Primary: Number of Participants in the Intent to Treat Population With Decrease in Plasma Intact Parathyroid Hormone (iPTH) of ≥30% From Pre-treatment Baseline Values — 6; 46…
Hepatitis B, Chronic
Primary: Percentage of Participants With HBeAg Seroconversion at 24 Weeks After End of Treatment (EOT)/POP in Groups A and B — 25.7; 6 percentage of participants — p== 0.0043
Asthma
Primary: Change From Baseline in Morning Peak Expiratory Flow (PEF) — 15.23; 14.79; 17.37; 5.40 liters/minute — p=0.0116
CHRONIC MYELOGENOUS LEUKEMIA
Primary: Rate of Confirmed Best Cumulative Complete Molecular Response (CMR) — 13; 6; 91; 97 Participants — p=0.1083
Seizures · Epilepsies, Partial · Epilepsy, Complex Partial
Primary: Time to Next Seizure or Rescue Medication During the Double-blind Period (Kaplan-Meier 50th Percentile) — 5.92; NA Hours — p=0.012
Epilepsy
Primary: Percent Reduction Over Placebo for Partial Onset Seizure (Type I) Frequency Over the Treatment Period Standardized to a 28-day Duration — 22.8; 23.2; 0 Percentage of…
Epilepsy
Primary: Percentage of Subjects Who Achieved a Clinically Meaningful Reduction of Nonpsychotic Behavioral Side Effects Based on the Investigator's Overall Assessment From Study…
Renal Failure
Primary: Evaluation of AUC(0-24) for Envarsus XR and IR-Tac — 251.9; 247.9 ng*hr/mL
Hypertension
Primary: Mean Reduction In Systolic Blood Pressure (SBP) After 18 Weeks of Treatment From Baseline — 150.6; 151.6; -24.7; -25.9 millimeters of mercury (mmHg) — p=<0.001